glp-1 gip therapy alternatives after discontinuation Weight maintenance of therapies Interest in Treatment with GLP-1

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

What is Retatrutide

Learn about GLP-1 receptor agonists (exenatide, liraglutide, semaglutide, tirzepatide) their mechanism, dosing, cautions, side effects, and interactions

Yale Medicine experts explain who qualifies, who can prescribe, and what to expect.

Due to a short plasma half-life of native GLP-1, several synthesized GLP-1 receptor agonists (RAs) were developed for type 2 diabetes mellitus (DM) treatment

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two gut hormones, defined incretins, responsible for the amplification of insulin secretion after oral glucose intake